Aspen Grove Capital’s GSK GSK Stock Holding History

Aspen Grove Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Sell	23,082 -272	-1%	-$14.4K	0.18%	66
2026 Q1	$1.3M	Buy	23,354 +1,571	+7%	+$85.1K	0.25%	56
2025 Q4	$1.08M	Sell	21,783 -7,176	-25%	-$335K	0.19%	62
2025 Q3	$1.26M	Sell	28,959 -5,924	-17%	-$231K	0.21%	60
2025 Q2	$1.35M	Buy	34,883 +841	+2%	+$32.1K	0.23%	57
2025 Q1	$1.33M	Buy	34,042 +3,258	+11%	+$119K	0.26%	60
2024 Q4	$1.05M	Sell	30,784 -1,470	-5%	-$52.9K	0.22%	61
2024 Q3	$1.33M	Sell	32,254 -7	-0%	-$286	0.29%	54
2024 Q2	$1.25M	Buy	32,261 +64	+0.2%	+$2.69K	0.3%	54
2024 Q1	$1.39M	Hold	32,197	–	–	0.39%	49
2023 Q4	$1.2M	Buy	32,197 +174	+0.5%	+$6.25K	0.37%	53
2023 Q3	$1.17M	Buy	32,023 +146	+0.5%	+$5.18K	0.44%	47
2023 Q2	$1.14M	Buy	31,877 +705	+2%	+$25.3K	0.37%	61
2023 Q1	$1.11M	Buy	31,172 +1,164	+4%	+$40.7K	0.49%	47
2022 Q4	$1.06M	Buy	+30,008	New	+$1,000K	0.49%	47

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aspen Grove Capital's GSK Position: Q2 2026 in Review

Aspen Grove Capital reduced its GSK (GSK) stake by 1.2% in Q2 2026, selling an estimated $14.4K and leaving 23,082 shares worth $1.22M. The position accounts for 0.18% of the portfolio, ranked #66.

Aspen Grove Capital first reported a position in GSK in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.39M in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Aspen Grove Capital held 23,082 shares of GSK worth $1.22M as of Q2 2026.
Aspen Grove Capital sold 272 GSK shares in Q2 2026, an estimated $14.4K.
GSK made up 0.18% of Aspen Grove Capital's portfolio in Q2 2026, its #66 holding.
Aspen Grove Capital first reported a position in GSK in Q4 2022 and has held it in 15 quarters since.
Aspen Grove Capital's GSK position peaked at $1.39M in Q1 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Aspen Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.